More than 90 Million Cervical Cancer Cases Reported Globally

Renub Research has announced its recent publication on “Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast”. The report gives a comprehensive picture of Global Cervical Cancer Screening Market with available diagnostic test pursued by developed, developing and under-privilege countries. In addition volume of patients diagnosed with cervical cancer and their mortality rate is also mentioned in this report. As of now cervical cancer cases is rising globally, Asia and North America both have reported more than 90 Million cervical cancer cases for the year 2016.

Cervical cancer is malignant tumour of the cervix and affecting women all over the world. Cervical cancer is a disease that impacted patients after long period, early diagnosed and treatment of precancerous lesions is considered to be more effective in women who sequentially take part in screening programs. Pap smear test is used at large-scale screening technique in European countries; however, HPV test is steadily gaining accommodation.
Significant measures taken by government and public awareness initiatives have reinforced HPV testing and immunization. Moreover, growing acceptance of the HPV test especially in the untapped developing markets will deliver substantial growth performance.

In low-income countries, VIA (Visual inspection with acetic acid) is used as a screening for cervical cancer due to lower health infrastructure and fund PAP smear and HPV test is not viable in these countries. Over the next decades, new and effective screening (VIA test) and early treatment technique will be the elementary drivers of reduced death from cervical cancer. Many international NGOs have been establishing pilot programme and make technical details available to respective governments.

ASCO Published Worldwide Guidance for HPV Vaccination for Cervical Cancer Prevention
The American Society of Clinical Oncology (ASCO) has recently published recommendation and guidelines for human papillomavirus (HPV) vaccination for how to prevent cervical cancer. The guideline recommends 4 level resource setting: Basic, Limited, Enhanced, and Maximal.

For More Information: http://www.renub.com/globally-asia-and-north-america-both-have-reported-more-than-90-million-cervical-cancer-cases-in-2016-27-nd.php

Contact Us

Rajat Gupta
Business Development Manager
Email: info@renub.com
Phone: +1-678-302-0700 (USA), +91-120-421-9822 (India)
Web: http://www.renub.com

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in today’s ultra-competitive markets.

225 Kristie Ln, Roswell, GA 30076, United States

This release was published on openPR.